90 likes | 104 Views
The Clinton Foundation monitors ARV orders to track pricing, lead times, quantities, and provide feedback to suppliers and organizations.
E N D
CHAI ARV Procurement Database Clinton Foundation HIV/AIDS Initiative November 7, 2005
The Clinton Foundation monitors ARV orders placed under our agreements for several reasons: • Monitor pricing to determine if countries are accessing CHAI prices • Monitor lead times between order placement and delivery • Track quantities purchased under CHAI agreements • Provide feedback to partner suppliers and organizations
Purchasing country Purchasing agent Order number Order date Invoice date Manufacturer Factory Product number Batch Expiration date Generic name Acronym Brand Form Concentration Pack Size Number of packs US$/pack Total US$/pack (inc. S&H) The order tracking database strives to capture similar data items as the GPRM
Currently the database contains information on 25 countries, capturing 185,000 patient years of treatment
The overall results reveal that stavudine, lamivudine and nevirapine are the most commonly procured 1st line drugs
Fixed dose combinations make up 55% of the total volume of formulations procured AZT+3TC+NVP • The fixed dose formulation of d4t+3TC+NVP was ordered with highest frequency (45% of total volume) • AZT+3TC was the second most common fixed dose ordered, at 9% • Single pill formulations of the 1st line drugs (AZT, d4t, 3TC, NVP and EFV) make up 39% of total volume d4t+3TC AZT+3TC 2nd Line d4t+3TC+NVP 1st Line Single Pills
Regionally, the data reveals that the Latin American market may behave differently than the African market Stavudine vs. Zidovudine(% of total volume) 2nd Line Uptake(% of total volume) 2ndLine 1stLine AZT d4t
Pediatric order data reveals that syrups are procured in higher volume than pills # of pills (millions) ml of solution (millions) Solution Pills *Includes CHAI procurement in: Cambodia, China, DR, India, Kenya, Lesotho, Malawi, Namibia, Rwanda, Tanzania, Uganda, Zambia, Zimbabwe; Does not include 2nd Line drugs, comprising an additional 20 – 30% of volume
Pediatric patients are expected to comprise 10% of total people on treatment by 2008 Number of patients (000s), select CHAI Consortium Countries* Children Adults *Includes: Angola, Bahamas, Brazil, Cambodia, China, DR, Ethiopia, Haiti, India, Jamaica, Kenya, Lesotho, Mozambique, OECS, Rwanda, Tanzania, Zambia